Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 3/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | VEGFA | P15692 | 2/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | EYA2 | O00167 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11087204 | 0.89 | HSPB1 (0.66) | HSPB1VCAM1SLC22A12LMNAALDH1A1 | |
| SCHEMBL2030047 | 0.83 | ESRRA (0.51) | VCAM1SLC22A12LMNAALDH1A1HTT | |
| SCHEMBL2030779 | 0.83 | VCAM1 (0.57) | HSPB1EPAS1VCAM1VEGFASLC22A12 | |
| SCHEMBL11779619 | 0.83 | HSPB1 (0.68) | HSPB1VCAM1SLC22A12ALDH1A1MAPT | |
| SCHEMBL6052442 | 0.83 | VCAM1 (0.53) | HSPB1VCAM1LMNAALDH1A1HTT | |
| SCHEMBL11095242 | 0.83 | PLA2G7 (0.48) | HSPB1EPAS1VCAM1SLC22A12LMNA | |
| SCHEMBL11088409 | 0.82 | VCAM1 (0.60) | HSPB1EPAS1VCAM1SLC22A12LMNA | |
| SCHEMBL11099104 | 0.82 | VCAM1 (0.51) | HSPB1VCAM1LMNAALDH1A1HTT | |
| SCHEMBL826371 | 0.81 | LMNA (0.48) | HSPB1VCAM1SLC22A12LMNAALDH1A1 | |
| SCHEMBL29525543 | 0.81 | LMNA (0.48) | HSPB1VCAM1SLC22A12LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1722789-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | Amgen Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-7041691-B1 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2005086904-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | TULARIK INC. | 2004-12-09 | — | — | US | disclosed |
| US-6770648-B2 | ANTIDIABETIC AGENTS | TULARIK INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | TULARIK INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1192137-A1 | COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY | Tularik Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | HSPB1 370/4885EPAS1 551/4885VCAM1 1654/4885 |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | HSPB1 370/4885EPAS1 551/4885VCAM1 1654/4885 |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | PPARG, PPARA, PPARD | HSPB1 595/4885EPAS1 911/4885VCAM1 3511/4885 |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | PPARG, PPARA, PPARD | HSPB1 553/4885EPAS1 895/4885VCAM1 3553/4885 |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | PPARD, PPARG, PPARA | HSPB1 316/4885EPAS1 1318/4885VCAM1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.